Lung cancer trials in Greece

In Greece 70 Also abroad 2733

70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Athens, Thessaloniki
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Athens, Chaïdári
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Athens, Chaïdári, Heraklion, Kifissia, Larissa, Pireas, Thessaloniki
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Athens, Pireas
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
No phaseTaking people
Analysis of Whole Exome and Transcriptome Sequencing to Identify Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC)
Where
Athens, Kavala, Pátrai, Thessaloniki
Age
18 years and over
People
300 worldwide
Run by
Hellenic Cooperative Oncology Group
See details and how to joinNCT07900581
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Athens, Larissa
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Athens, Efkarpia, Heraklion, Kifissia, Larissa, Patras, Pireas, Thessaloniki
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00 · EU 2023-509340-10-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Athens, Efkarpia, Larissa, Patras, Pireas, Thessaloniki
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Athens, Larissa, Patras, Thessaloniki
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Athens, Larissa, Rio, Thessaloniki
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Athens, Chaïdári, Heraklion, Larissa, Patras, Pireas, Thessaloniki
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00 · EU 2025-522818-23-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
Athens, Thessaloniki
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
Phase 2Taking people
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Where
Athens, Thessaloniki
Age
18 years and over
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Athens, Rio, Thessaloniki
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 3Taking people
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Where
Athens, Thessaloniki
Age
18 years and over
People
550 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT07625644
Phase 2/3Not yet taking people in Greece
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Where
Athens, Chaïdári, Thessaloniki
Age
18 years and over
People
173 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 · EU 2025-521908-22-00
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Athens, Pireas, Thessaloniki
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 2/3Taking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
Athens, Chaïdári, Thessaloniki
Age
18 years and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Athens, Cholargos, Heraklion, Larissa, Patras, Pireas, Thessaloniki
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Athens, Thessaloniki
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Athens, Larissa, Thessaloniki
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00
Phase 3Taking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
Athens, Heraklion, Larissa, Nea Kifissia, Patra, Piraeus, Thessaloniki
Age
18 years and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
Phase 3Taking people
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Where
Athens, Pireas, Thessaloniki
Age
18 years and over
People
120 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Athens, Efkarpia
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Athens, Larissa, Maroussi, Thessaloniki
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00